<DOC>
	<DOCNO>NCT00659438</DOCNO>
	<brief_summary>This randomize , double-blind phase II trial ass efficacy safety bicalutamide ( Casodex® ) associate ZD6474 ( Zactima™ ) placebo patient castration-refractory metastatic prostate cancer without clinical symptom related disease progression . The study blind , subject randomise ( 1:1 ratio ) either ZD6474 300 mg placebo . The blinded design ensure robust , unbiased data collection assessment . Placebo control necessary ensure robust assessment PSA PFS , acceptable subject population subject also receive bicalutamide 150 mg o.d . Subjects continue study treatment reach objective biological disease progression unacceptable toxicity withdrawal consent end trial ( event occur first ) . The end study fix 12 month last randomise patient 's first dose study treatment .</brief_summary>
	<brief_title>Efficacy Safety Zactima™ Patients With Castration-refractory Metastatic Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<criteria>Males present confirmed histological diagnosis adenocarcinoma prostate evidence metastasis ( include bone , lymph node , site ) radiologically histologically document despite serum testosterone ≤1.73 nmol/L ( 50 ng/dL ) prove castration , evidence biochemical progression prostate cancer , document rise PSA . Radiotherapy surgery antiandrogens ( except LHRH analogue ) bilateral orchiectomy within 30 day precede Visit 1 . Incompletely heal surgical incision . Concomitant anticancer therapy surgical castration continuous medical castration . Biology restriction . Clinical significant cardiovascular event presence cardiac disease opinion Investigator increase risk ventricular arrhythmia . History arrhythmia symptomatic require treatment ( CTCAE grade 3 ) , symptomatic despite treatment , asymptomatic sustain ventricular tachycardia . Subjects atrial fibrillation control medication permit . Hypertension control medical therapy ECG /QTc prolongation Presence leave bundle branch block ( LBBB ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>